Diagnostic performance of a 3-d automated quantification method of dopamine d2 receptor spect studies in the differential diagnosis of parkinsonism

Nuclear Medicine Communications

Volumn 26, Issue 1, 2005, Pages 39-43

  Pöpperl, Gabriele ^a   Radau, Perry ^a   Linke, Rainer ^a   Hahn, Klaus ^a   Tatsch, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Automated quantification; Parkinsonian syndromes

Indexed keywords

DOPAMINE 2 RECEPTOR; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE;

ADULT; AGED; ARTICLE; AUTOMATION; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EXTRAPYRAMIDAL SYNDROME; FEMALE; FRONTAL CORTEX; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; RECEIVER OPERATING CHARACTERISTIC; ROC CURVE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATE CORTEX; THREE DIMENSIONAL IMAGING;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BENZAMIDES; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PYRROLIDINES; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 13244287806     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200501000-00007     Document Type: Article

References (21)

1. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42:1142-1146.
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-184.
3. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26:171-182.
4. Brücke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S, Podreka I. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000; 247(suppl 4):2-7.
5. Tatsch K. Imaging of the dopaminergic system in parkinsonism with SPET. Nucl Med Commun 2001; 22:819-827.
6. Joyce JN. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases. Brain Res 1993; 600:156-160.
7. 3H]spiperone binding dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol 1984; 99:167-175.
8. Churchyard A, Donnan GA, Hughes A, Howells DW, Woodhouse D, Wong JY, et al. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors. Ann Neurol 1993; 34:219-226.
9. Pascual J, Berciano J, Grijalba B, et al. Dopamine D1 and D2 receptors in progressive supranuclear palsy: an autoradiographic study. Ann Neurol 1992; 32:703-707.
10. Verhoeff NP, Kapucu O, Sokole-Busemann E, van Royen EA, Janssen AG. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. J Nucl Med 1993; 34:2076-2084.
11. 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med 2000; 41:220-227.
12. Swets JA. ROC analysis applied to the evaluation of medical imaging techniques. Invest Radiol 1979; 14:109-121.
13. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
14. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57:672-681.
15. Quinn N. Multiple system atrophy - the nature of the beast. J Neurol Neurosurg Psychiatry 1989; 52(suppl):78-89.
16. Schwarz J, Kraft E, Vogl T, Arnold G, Tatsch K, Oertel WH. Relative quantification of signal on T2-weighted images in the basal ganglia: limited value in differential diagnosis of patients with parkinsonism. Neuroradiology 1999; 41:124-128.
17. Habraken JB, Booij J, Slomka P, Sokole EB, van Royen EA. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med 1999; 40:1091-1097.
18. Kung HF, Alavi A, Chang W, Kung MP, Keyes JW, Jr., Velchik MG, et al. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 1990; 31:573-579.
19. Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991; 11:220-228.
20. Costa DC, Verhoeff NP, Cullum ID, Ell PJ, Syed GM, Barrett J, et al. In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans. Eur J Nucl Med 1990; 16:813-816.
21. Camps M, Cortes R, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience 1989; 28:275-290.